Stock Rating Report for AEZS

Ticker: 

Stock Information

Ticker AEZS
Company Name AEterna Zentaris Inc (USA)
Current Price $1.78
Previous Close $1.78
Industry Biotechnology
Sector HEALTHCARE
Long Stop Loss Members Only
Short Stop Loss Members Only
Expected Move Members Only
Optionable? Yes

StockProphet Ratings

Join today to see our Technical, Fundamental, and Composite Stock Rating for this stock.

Sector Risks

Sign up for MarketProphet today to see our 30, 60, and 90 day risk assessment for this stock.


Chart

We use technical analysis and fundamental analysis to recommend ratings for thousands of stocks. If you had a subscription, this space would show our 3 year history of trades for AEZS. However, we only show it to our subscribers.

We update our ratings and stop losses EVERY WEEK.

Don't miss out on what we recommend for AEterna Zentaris Inc (USA) next week. Sign up today and start making money!

Demand Fundamentals

Demand Fundamental Value Score Rating
Qtr/Qtr Revenue Growth Members Only
Qtr/Qtr Earnings Growth Members Only
Year/Year Revenue Growth Members Only
Year/Year Earnings Growth Members Only
Multi-Year Revenue Growth Members Only
Multi-Year Earnings Growth Members Only
Relative PE Ranking Members Only
Return on Equity Members Only
Yield Members Only
Institutional Holding Members Only
Stock Price Members Only
Relative Fundamental Ranking Members Only
Total Score Members Only

Demand Technicals

Demand Technical Value Score Rating
Recommended Condition Members Only
Trading Zone Members Only
Average Trading Volume Members Only
Industry Bull/Bear Condition Members Only
Sector Bull/Bear Condition Members Only
Current Signal Start Date Members Only
Total Score Members Only

Company Profile

Aeterna Zentaris Inc. operates as a late-stage drug development company specialized in oncology and endocrine therapy. Its lead oncology compounds include perifosine, a PI3K/Akt pathway inhibitor that is in Phase 3 registration trial for refractory advanced colorectal cancer and multiple myeloma- and AEZS-108, a doxorubicin-targeted conjugate in Phase II for the treatment of ovarian, endometrial, castration refractory prostate, and refractory bladder cancer. The company's lead endocrinology compound, AEZS-130, is an oral ghrelin antagonist in Phase III trial as a diagnostic test for adult growth hormone deficiency. Its pipeline also includes earlier-stage compounds, such as AEZS-112 that is in a Phase I trial in advanced solid tumors and lymphoma, as well as AEZS-120, an anti-cancer vaccine in pre-clinical development. The company was founded in 1991 and is headquartered in Quebec City, Canada.


Latest News

Tue, 07 Feb 2012 13:20:00 GMTYM BioSciences and AEterna Zentaris -- Starting Strong in 2012
Tue, 07 Feb 2012 12:30:00 GMTAeterna Zentaris to Present at BIO CEO Investor and RBC Capital Markets Global Healthcare Conferences in New York
Tue, 07 Feb 2012 12:30:00 GMTAeterna Zentaris to Present at BIO CEO Investor and RBC Capital Markets Global Healthcare Conferences in New York
Fri, 03 Feb 2012 22:33:50 GMT3 Hot Picks On The Way Up
Fri, 03 Feb 2012 12:37:00 GMTAeterna Zentaris Reports Updated Phase 1 Trial Results for AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer at ASCO GCS Meeting
Fri, 03 Feb 2012 12:37:00 GMTAeterna Zentaris Reports Updated Phase 1 Trial Results for AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer at ASCO GCS Meeting
Wed, 01 Feb 2012 12:04:58 GMTZacks #1 Rank Additions for Wednesday
Mon, 30 Jan 2012 22:52:17 GMTAntares's New RA Treatment Method Has Large Market Potential
Fri, 27 Jan 2012 17:23:28 GMT4 Biotech Stocks To Consider Buying, 2 To Sell In 2012
Thu, 26 Jan 2012 12:30:00 GMTAeterna Zentaris: Updated Interim Phase 1 Trial Results for AEZS-108 in Prostate Cancer To Be Presented at Upcoming ASCO GCS Meeting in San Francisco
Thu, 26 Jan 2012 12:30:00 GMTAeterna Zentaris: Updated Interim Phase 1 Trial Results for AEZS-108 in Prostate Cancer To Be Presented at Upcoming ASCO GCS Meeting in San Francisco
Thu, 26 Jan 2012 09:59:33 GMTZacks #1 Rank Additions for Thursday
Wed, 25 Jan 2012 13:20:00 GMTBiotechnology Industry on the Upswing -- Aeterna Zentaris and Elite Pharmaceuticals to Benefit
Wed, 25 Jan 2012 02:51:57 GMTStock Boards: Weeding Through The Nonsense, Getting To The Facts.
Mon, 23 Jan 2012 22:56:00 GMTAeterna Zentaris Announces "At-the-Market" Issuance Program
Mon, 23 Jan 2012 22:56:00 GMTAeterna Zentaris Announces "At-the-Market" Issuance Program
Mon, 23 Jan 2012 18:02:53 GMTThe Best Biotech Stocks Of 2012
Thu, 19 Jan 2012 16:41:11 GMT2 High-Flying Biotechs Face a New Hurdle
Thu, 19 Jan 2012 01:42:51 GMT2 High-Flying Biotechs Face a New Hurdle
Thu, 19 Jan 2012 01:31:29 GMTDon't Read Too Much Into This Partnership
News provided by Yahoo! Finance
Home | StockProphet | Top 100 Stocks | New Hot Stock Picks | Sector Analyzer | Industry Analyzer | Member's Area | FAQ | Contact Us | Privacy and Security
(C) Copyright CycleProphet, Inc.  All Rights Reserved.

*Past performance does not guarantee future results. CycleProphet makes no representations or warrants that just because a stock would have made a profit in the past, using CycleProphet buy recommendations or sell recommendations, it will make any profits in the future. It is possible that these same stocks will lose money in the future using the CycleProphet stock recommendations.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither CycleProphet nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the CycleProphet site, a user agrees not to redistribute the information found therein.

thinkorswim, Division of TD AMERITRADE, Inc. and CycleProphet are separate, unaffiliated companies and are not responsible for each other's services and products.